Q2 2021 Earnings Estimate for Teleflex Incorporated (NYSE:TFX) Issued By Jefferies Financial Group

Teleflex Incorporated (NYSE:TFX) – Stock analysts at Jefferies Financial Group dropped their Q2 2021 EPS estimates for Teleflex in a note issued to investors on Thursday, April 29th. Jefferies Financial Group analyst R. Denhoy now forecasts that the medical technology company will earn $2.66 per share for the quarter, down from their prior estimate of $2.84. Jefferies Financial Group also issued estimates for Teleflex’s FY2021 earnings at $12.70 EPS, Q2 2022 earnings at $3.46 EPS, Q3 2022 earnings at $3.68 EPS, Q4 2022 earnings at $4.41 EPS and FY2022 earnings at $14.89 EPS.

TFX has been the subject of a number of other research reports. Raymond James raised their price target on shares of Teleflex from $460.00 to $480.00 and gave the stock a “strong-buy” rating in a research report on Thursday, March 18th. KeyCorp raised their price target on shares of Teleflex from $382.00 to $441.00 and gave the stock an “overweight” rating in a research report on Friday, January 8th. SVB Leerink raised their price target on shares of Teleflex from $475.00 to $485.00 and gave the stock an “outperform” rating in a research report on Friday, April 30th. Needham & Company LLC raised their price target on shares of Teleflex from $406.00 to $445.00 and gave the stock a “buy” rating in a research report on Wednesday, January 6th. Finally, Wells Fargo & Company raised their price objective on Teleflex from $425.00 to $455.00 and gave the stock an “overweight” rating in a research note on Monday, January 11th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $460.44.

TFX stock opened at $412.68 on Monday. Teleflex has a twelve month low of $312.33 and a twelve month high of $449.38. The company has a current ratio of 2.99, a quick ratio of 1.88 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $19.29 billion, a P/E ratio of 53.11, a PEG ratio of 2.63 and a beta of 1.14. The firm has a 50 day simple moving average of $422.17 and a 200-day simple moving average of $394.45.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, April 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.43. Teleflex had a net margin of 14.66% and a return on equity of 16.33%.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 15th. Shareholders of record on Friday, May 14th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, May 13th. Teleflex’s payout ratio is 12.20%.

Hedge funds have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. lifted its stake in Teleflex by 152.0% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 63 shares of the medical technology company’s stock valued at $26,000 after buying an additional 38 shares during the last quarter. Vantage Consulting Group Inc bought a new stake in Teleflex in the fourth quarter valued at $26,000. Exchange Traded Concepts LLC lifted its stake in Teleflex by 366.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 84 shares of the medical technology company’s stock valued at $35,000 after buying an additional 66 shares during the last quarter. Graves Light Private Wealth Management Inc. bought a new stake in Teleflex in the fourth quarter valued at $50,000. Finally, Freedman Financial Associates Inc. bought a new stake in Teleflex in the fourth quarter valued at $53,000. Institutional investors own 89.78% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Read More: Non-Fungible Token (NFT) Explained

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.